<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01651780</url>
  </required_header>
  <id_info>
    <org_study_id>TMC-BIV-11-02</org_study_id>
    <secondary_id>2012‐000632‐26</secondary_id>
    <nct_id>NCT01651780</nct_id>
  </id_info>
  <brief_title>Open-label, Randomized Trial in Participants Undergoing TAVR to Determine Safety &amp; Efficacy of Bivalirudin vs UFH</brief_title>
  <acronym>BRAVO 2/3</acronym>
  <official_title>Effect of Bivalirudin on Aortic Valve Intervention Outcomes 2/3 (BRAVO 2/3)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Medicines Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The Medicines Company</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to assess the safety and efficacy of using bivalirudin instead
      of unfractionated heparin (UFH) in transcatheter aortic valve replacements (TAVR). The
      primary hypothesis of BRAVO 3 was that bivalirudin would reduce major bleeding compared with
      heparin in TAVR procedures. Results for all participants enrolled into the randomized trial
      (BRAVO 3) are presented.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2012</start_date>
  <completion_date type="Actual">June 2015</completion_date>
  <primary_completion_date type="Actual">June 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Major Bleeding (BARC ≥3b) at 48 Hours or Before Hospital Discharge</measure>
    <time_frame>at 48 hours or discharge, whichever occurs first</time_frame>
    <description>Major bleeding (Bleeding Academic Research Consortium [BARC] type ≥3b) was defined as follows:
Bleeds that were evident clinically, or by laboratory or imaging results, which resulted in surgical intervention or administration of IV vasoactive drugs; overt bleeds with a hemoglobin drop of at least 5 grams per deciliter (g/dL); and bleeding that caused cardiac tamponade.
BARC 3c includes intracranial or intraocular bleeds that compromised vision.
BARC type 4 (Coronary Artery Bypass Grafting [CABG]-related bleeding) includes perioperative intracranial bleeding within 48 hours, bleeds that result in reoperation following closure of sternotomy for the purpose of controlling bleeding, bleeds that result in treatment with transfusion of ≥5 units of whole blood or packed red blood cells within a 48 hour period; and chest tube output ≥2 liters (L) within a 24-hour period.
BARC type 5, fatal bleeding, describes bleeds that directly result in death with no other cause.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Net Adverse Clinical Events (NACE) at up to 30 Days</measure>
    <time_frame>up to 30 days after procedure</time_frame>
    <description>The net adverse cardiac events (NACE) at 30 days is the composite of major adverse cardiovascular events (MACE) + major bleeding (BARC type ≥3b). The composite of MACE is defined as all-cause mortality, myocardial infarction (MI), and stroke. A participant was defined to have a composite event if the participant experienced at least 1 of the components. If the participant did not have any of the components, then he or she did not have the composite endpoint. If a participant had more than 1 of the components, he or she was only counted once in the determination of the total number of participants experiencing the composite endpoint.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>NACE at 48 Hours or Before Hospital Discharge</measure>
    <time_frame>at 48 hours or before hospital discharge, whichever occurred earlier</time_frame>
    <description>NACE at 48 hours or before hospital discharge is the composite of major adverse cardiovascular events (MACE) + major bleeding (BARC type ≥3b). The composite of MACE is defined as all-cause mortality, MI, and stroke. A participant was defined to have a composite event if the participant experienced at least 1 of the components. If the participant did not have any of the components, then he or she did not have the composite endpoint. If a participant had more than 1 of the components, he or she was only counted once in the determination of the total number of participants experiencing the composite endpoint.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major Adverse Cardiac Events (MACE) Including Death, Non-fatal MI, and Stroke</measure>
    <time_frame>at 48 hours or before hospital discharge, whichever occurred earlier, and at up to 30 days (±7 days)</time_frame>
    <description>The percentage of participants reporting a MACE overall and the individual components of MACE (including death, non-fatal MI, and stroke) are presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major Bleeding According to Additional Scales (VARC, TIMI, GUSTO, ACUITY/HORIZONS)</measure>
    <time_frame>at 48 hours or hospital discharge, whichever occurred earlier, and at up to 30 days (±7 days) follow-up</time_frame>
    <description>Percentage of participants with major bleeding according to the following scales:
Valve Academic Research Consortium (VARC)=life threatening, disabling bleeding, or major bleeding
Thrombolysis in Myocardial Infarction (TIMI)=major bleeding
Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO)=severe or moderate
Acute Catheterization and Urgent Intervention Triage StrategY (ACUITY)/Harmonizing Outcomes with RevasculariZatiON and Stents (HORIZONS)=major bleeding</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Transient Ischemic Attack</measure>
    <time_frame>at 48 hours or before hospital discharge, whichever occurred earlier, and at up to 30 days (±7 days)</time_frame>
    <description>The percentage of participants reporting transient ischemic attack is presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute Kidney Injury</measure>
    <time_frame>at 48 hours or hospital discharge, whichever occurred earlier, and at up to 30 days (±7 days) follow-up</time_frame>
    <description>The percentage of participants reporting acute kidney injury is presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major Vascular Complications</measure>
    <time_frame>at 48 hours or before hospital discharge, whichever occurred earlier, and at up to 30 days (±7 days)</time_frame>
    <description>The percentage of participants reporting a major vascular complications as defined by VARC is presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acquired Thrombocytopenia</measure>
    <time_frame>at 48 hours or before hospital discharge, whichever occurred earlier, and at up to 30 days (±7 days)</time_frame>
    <description>The percentage of participants reporting acquired thrombocytopenia is presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>New Onset Atrial Fibrillation/Flutter</measure>
    <time_frame>at 48 hours or before hospital discharge, whichever occurred earlier, and at up to 30 days (±7 days)</time_frame>
    <description>The percentage of participants reporting new onset atrial fibrillation/flutter is presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Timing Effect on Bleeding Event Rate up to 48 Hours or Hospital Discharge</measure>
    <time_frame>Up to 48 hours after procedure or at hospital discharge (but also includes any subsequent hospitalizations)</time_frame>
    <description>The effect of timing on bleeding event rates (the percentage of participants with an incidence of major bleeding) is presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bleeding BARC 3a, BARC Types 1 or 2, and TIMI Minor</measure>
    <time_frame>at 48 hours or hospital discharge, whichever occurred earlier, and at up to 30 days (±7 days) follow-up</time_frame>
    <description>The percentage of participants with moderate bleeding as defined by BARC 3a and minor bleeding as defined as BARC type 1 and 2 and TIMI minor is presented.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">803</enrollment>
  <condition>Severe Aortic Stenosis</condition>
  <condition>Transcatheter Aortic Valve Replacement</condition>
  <condition>Aortic Valve Replacement</condition>
  <arm_group>
    <arm_group_label>Bivalirudin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Bivalirudin administered as a bolus and intravenous (IV) infusion during TAVR. It was recommended that the bolus (0.75 milligrams per kilogram [mg/kg]) be directly administered through the valve delivery sheath immediately following its successful delivery via percutaneous femoral access. Systemic IV administration of the bolus dose was also acceptable. The bivalirudin IV infusion was initiated immediately after the bolus administration. All wires, catheters, and sheaths were to be flushed with heparinized saline.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Unfractionated heparin (UFH)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The dose of UFH adhered to the standard institutional practice. An activated clotting time (ACT) target ≥250 seconds was recommended. All wires, catheters, and sheaths were to be flushed with heparinized saline.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bivalirudin</intervention_name>
    <description>Bivalirudin is an anticoagulant that binds directly to thrombin in a bivalent and reversible fashion.</description>
    <arm_group_label>Bivalirudin</arm_group_label>
    <other_name>AngioMAX</other_name>
    <other_name>Angiox</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Unfractionated Heparin</intervention_name>
    <description>Unfractionated heparin is an anticoagulant.</description>
    <arm_group_label>Unfractionated heparin (UFH)</arm_group_label>
    <other_name>Heparin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males and females, ≥18 years of age

          -  High risk (Euroscore ≥18, or considered inoperable) for surgical aortic valve
             replacement

          -  Undergoing TAVR via transfemoral arterial access

          -  Provide written informed consent before initiation of any study related procedures

        Exclusion Criteria:

          -  Any known contra‐indication to the use of bivalirudin (except presence of severe renal
             impairment [glomerular filtration rate (GFR) &lt;30 milliliters (mL)/minute] since these
             participants will be included in the trial or UFH

          -  Refusal to receive blood transfusion

          -  Mechanical valve (any location) or mitral bioprosthetic valve

          -  Extensive calcification of the common femoral artery, or minimal luminal diameter &lt;6.5
             millimeters (mm)

          -  Use of elective surgical cut-down for transfemoral access

          -  Concurrent performance of percutaneous coronary intervention with TAVR

          -  International normalized ratio (INR) ≥2 on the day of TAVR procedure or known history
             of bleeding diathesis

          -  History of hemorrhagic stroke, intracranial hemorrhage, intracerebral mass or
             aneurysm, or arteriovenous malformation

          -  Severe left ventricular dysfunction (left ventricular ejection fraction &lt;15%)

          -  Severe aortic regurgitation or mitral regurgitation (4+)

          -  Hemodynamic instability (for example, requiring inotropic or intra-aortic balloon pump
             support) within 2 hours of the procedure

          -  Dialysis dependent

          -  Administration of thrombolytics, glycoprotein IIb/IIIa inhibitors, or warfarin in the
             3 days prior to the procedure

          -  Acute myocardial infarction, major surgery, or any therapeutic cardiac procedure
             (other than balloon aortic valvuloplasty) within 30 days

          -  Percutaneous coronary intervention within 30 days

          -  Upper gastrointestinal or genitourinary bleed within 30 days

          -  Stroke or transient ischemic attack within 30 days

          -  Any surgery or biopsy within 2 weeks

          -  Administration of:

               -  UFH within 30 minutes of the procedure

               -  Enoxaparin within 8 hours of the procedure

               -  Fondaparinux or other low-molecular-weight heparins (LMWHs) within 24 hours of
                  the procedure

               -  Dabigatran, rivaroxaban, or other oral anti-Xa or antithrombin agent within 48
                  hours of the procedure

               -  Thrombolytics, glycoprotein IIb/IIIa inhibitor, or warfarin within 72 hours of
                  the procedure

          -  Absolute contraindications or allergy that cannot be pre-medicated to iodinated
             contrast

          -  Contraindications or allergy to aspirin or clopidogrel

          -  Known or suspected pregnant women or nursing mothers. Women of child‐bearing potential
             will be asked if they are pregnant and will be tested for pregnancy

          -  Previous enrollment in this study

          -  Treatment with other investigational drugs or devices within the 30 days preceding
             enrollment or planned use of other investigational drugs or devices before the primary
             endpoint of this study has been reached
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thierry Lefevre, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hôpital Privé Jacques Cartier</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Eberhardt Grube, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Bonn</affiliation>
  </overall_official>
  <overall_official>
    <last_name>George D Dangas, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>The Zena and Michael A. Wiener Cardiovascular Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Prodromos Anthopoulos, MD</last_name>
    <role>Study Director</role>
    <affiliation>The Medicines Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Montreal Heart Institute</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H1T 1C8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Paul´s Hospital Providence Health Care</name>
      <address>
        <city>Vancouver</city>
        <zip>V6Z1Y6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique Pasteur, Unité de Cardiologie Interventionnelle</name>
      <address>
        <city>Toulouse</city>
        <state>Cedex 3</state>
        <zip>31076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Toulouse</name>
      <address>
        <city>Toulouse</city>
        <state>Cedex 9</state>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Jean Minjoz, Service de Cardiologie</name>
      <address>
        <city>Besançon</city>
        <zip>25000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de Lyon</name>
      <address>
        <city>Bron</city>
        <zip>69500</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Cardiology, CHRU Lille</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Hospitalier Jacques Cartier</name>
      <address>
        <city>Massy</city>
        <zip>91300</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service de Cardiologie, Centre Hospitalo-Universitaire, Hôpital Charles-Nicolle</name>
      <address>
        <city>Rouen</city>
        <zip>76031</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Heart Centre, Clinic of Inner Medicine 1 Cardiology</name>
      <address>
        <city>Jena</city>
        <state>Lobeda Ost</state>
        <zip>07747</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Bonn</name>
      <address>
        <city>Bonn</city>
        <zip>53105</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum links der Weser Bremen</name>
      <address>
        <city>Bremen</city>
        <zip>28277</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Elisabeth-Krankenhaus Essen</name>
      <address>
        <city>Essen</city>
        <zip>45257</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Freiburg University</name>
      <address>
        <city>Freiburg</city>
        <zip>79106</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asklepios St. Georg Hamburg</name>
      <address>
        <city>Hamburg</city>
        <zip>20099</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Hamburg-Eppendorf</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinische Hochschule Hannover</name>
      <address>
        <city>Hannover</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universität Leipzig - Herzzentrum GmbH</name>
      <address>
        <city>Leipzig</city>
        <zip>04289</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsmedizin der Johannes Gutenberg-Universitat Mainz</name>
      <address>
        <city>Mainz</city>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LMU Munich, Klinikum der Universität München</name>
      <address>
        <city>Munich</city>
        <zip>81377</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Deutsches Herzzentrum München</name>
      <address>
        <city>München</city>
        <zip>80636</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Helios Heart Center Siegburg</name>
      <address>
        <city>Siegburg</city>
        <zip>53721</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ferraroto Hospital, University of Catania</name>
      <address>
        <city>Catania</city>
        <zip>95123</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale San Raffaele U.O. Cardiologia Interventistica</name>
      <address>
        <city>Milano</city>
        <zip>20132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero-Universitaria Pisana</name>
      <address>
        <city>Pisa</city>
        <zip>56124</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera San Camillo-Forlanini</name>
      <address>
        <city>Roma</city>
        <zip>00151</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Policlinico Umberto I, Università La Sapienza</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Antonius Ziekenhuis</name>
      <address>
        <city>Nieuwegein</city>
        <zip>3435</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Medical Center Utrecht</name>
      <address>
        <city>Utrecht</city>
        <zip>3584 CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cardiology University Hospital Basel</name>
      <address>
        <city>Basel</city>
        <zip>CH-4031</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinik Bern</name>
      <address>
        <city>Bern</city>
        <zip>3010</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Royal Sussex County Hospital</name>
      <address>
        <city>Brighton</city>
        <state>East Sussex</state>
        <zip>BN2 5BE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hammersmith Hospital</name>
      <address>
        <city>London</city>
        <zip>W12 0HS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Switzerland</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 24, 2012</study_first_submitted>
  <study_first_submitted_qc>July 26, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 27, 2012</study_first_posted>
  <results_first_submitted>January 9, 2017</results_first_submitted>
  <results_first_submitted_qc>January 9, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">February 27, 2017</results_first_posted>
  <last_update_submitted>March 9, 2017</last_update_submitted>
  <last_update_submitted_qc>March 9, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 7, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Transcatheter aortic valve replacement</keyword>
  <keyword>Aortic valve replacement</keyword>
  <keyword>Severe aortic stenosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aortic Valve Stenosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Calcium heparin</mesh_term>
    <mesh_term>Bivalirudin</mesh_term>
    <mesh_term>Heparin</mesh_term>
    <mesh_term>Hirudins</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Bivalirudin</title>
          <description>Bivalirudin administered as a bolus and intravenous (IV) infusion during transcatheter aortic valve replacement (TAVR). It was recommended that the bolus (0.75 milligrams per kilogram [mg/kg]) be directly administered through the valve delivery sheath immediately following its successful delivery via percutaneous femoral access. Systemic IV administration of the bolus dose was also acceptable. The bivalirudin IV infusion was initiated immediately after the bolus administration. All wires, catheters, and sheaths were to be flushed with heparinized saline.</description>
        </group>
        <group group_id="P2">
          <title>Unfractionated Heparin (UFH)</title>
          <description>The dose of UFH adhered to the standard institutional practice. An activated clotting time (ACT) target ≥250 seconds was recommended. All wires, catheters, and sheaths were to be flushed with heparinized saline.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="405"/>
                <participants group_id="P2" count="398"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Intent-To-Treat (ITT) Population</title>
              <participants_list>
                <participants group_id="P1" count="404"/>
                <participants group_id="P2" count="398"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received at Least 1 Dose of Study Drug</title>
              <participants_list>
                <participants group_id="P1" count="393">All but 1 participant in the bivalirudin group (withdrew consent) comprised the ITT population.</participants>
                <participants group_id="P2" count="394"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>BRAVO 2 Feasibility Cohort</title>
              <participants_list>
                <participants group_id="P1" count="65">1st 2 participants/site made up the bivalirudin feasibility cohort (BRAVO2) and analyzed separately.</participants>
                <participants group_id="P2" count="0">1st 2 participants/site made up the bivalirudin feasibility cohort (BRAVO2) and analyzed separately.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="394"/>
                <participants group_id="P2" count="388"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Physician decision: No 30-day visit</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Reason Not Specified: No 30-day visit</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Inclusion/Exclusion Criteria Not Met</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician decision: Day 30 visit &lt;23 day</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Participants in the ITT population.</population>
      <group_list>
        <group group_id="B1">
          <title>Bivalirudin</title>
          <description>Bivalirudin administered as a bolus and intravenous (IV) infusion during TAVR. It was recommended that the bolus (0.75 milligrams per kilogram [mg/kg]) be directly administered through the valve delivery sheath immediately following its successful delivery via percutaneous femoral access. Systemic IV administration of the bolus dose was also acceptable. The bivalirudin IV infusion was initiated immediately after the bolus administration. All wires, catheters, and sheaths were to be flushed with heparinized saline.</description>
        </group>
        <group group_id="B2">
          <title>Unfractionated Heparin (UFH)</title>
          <description>The dose of UFH adhered to the standard institutional practice. An ACT target ≥250 seconds was recommended. All wires, catheters, and sheaths were to be flushed with heparinized saline.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="404"/>
            <count group_id="B2" value="398"/>
            <count group_id="B3" value="802"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="82.3" spread="6.5"/>
                    <measurement group_id="B2" value="82.3" spread="6.5"/>
                    <measurement group_id="B3" value="82.3" spread="6.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="195"/>
                    <measurement group_id="B2" value="196"/>
                    <measurement group_id="B3" value="391"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="209"/>
                    <measurement group_id="B2" value="202"/>
                    <measurement group_id="B3" value="411"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36"/>
                    <measurement group_id="B2" value="38"/>
                    <measurement group_id="B3" value="74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Netherlands</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Italy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37"/>
                    <measurement group_id="B2" value="39"/>
                    <measurement group_id="B3" value="76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United Kingdom</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>France</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="108"/>
                    <measurement group_id="B2" value="106"/>
                    <measurement group_id="B3" value="214"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Switzerland</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Germany</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="180"/>
                    <measurement group_id="B2" value="173"/>
                    <measurement group_id="B3" value="353"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Major Bleeding (BARC ≥3b) at 48 Hours or Before Hospital Discharge</title>
        <description>Major bleeding (Bleeding Academic Research Consortium [BARC] type ≥3b) was defined as follows:
Bleeds that were evident clinically, or by laboratory or imaging results, which resulted in surgical intervention or administration of IV vasoactive drugs; overt bleeds with a hemoglobin drop of at least 5 grams per deciliter (g/dL); and bleeding that caused cardiac tamponade.
BARC 3c includes intracranial or intraocular bleeds that compromised vision.
BARC type 4 (Coronary Artery Bypass Grafting [CABG]-related bleeding) includes perioperative intracranial bleeding within 48 hours, bleeds that result in reoperation following closure of sternotomy for the purpose of controlling bleeding, bleeds that result in treatment with transfusion of ≥5 units of whole blood or packed red blood cells within a 48 hour period; and chest tube output ≥2 liters (L) within a 24-hour period.
BARC type 5, fatal bleeding, describes bleeds that directly result in death with no other cause.</description>
        <time_frame>at 48 hours or discharge, whichever occurs first</time_frame>
        <population>Participants in the ITT population.</population>
        <group_list>
          <group group_id="O1">
            <title>Bivalirudin</title>
            <description>Bivalirudin administered as a bolus and intravenous (IV) infusion during TAVR. It was recommended that the bolus (0.75 milligrams per kilogram [mg/kg]) be directly administered through the valve delivery sheath immediately following its successful delivery via percutaneous femoral access. Systemic IV administration of the bolus dose was also acceptable. The bivalirudin IV infusion was initiated immediately after the bolus administration. All wires, catheters, and sheaths were to be flushed with heparinized saline.</description>
          </group>
          <group group_id="O2">
            <title>Unfractionated Heparin (UFH)</title>
            <description>The dose of UFH adhered to the standard institutional practice. An ACT target ≥250 seconds was recommended. All wires, catheters, and sheaths were to be flushed with heparinized saline.</description>
          </group>
        </group_list>
        <measure>
          <title>Major Bleeding (BARC ≥3b) at 48 Hours or Before Hospital Discharge</title>
          <description>Major bleeding (Bleeding Academic Research Consortium [BARC] type ≥3b) was defined as follows:
Bleeds that were evident clinically, or by laboratory or imaging results, which resulted in surgical intervention or administration of IV vasoactive drugs; overt bleeds with a hemoglobin drop of at least 5 grams per deciliter (g/dL); and bleeding that caused cardiac tamponade.
BARC 3c includes intracranial or intraocular bleeds that compromised vision.
BARC type 4 (Coronary Artery Bypass Grafting [CABG]-related bleeding) includes perioperative intracranial bleeding within 48 hours, bleeds that result in reoperation following closure of sternotomy for the purpose of controlling bleeding, bleeds that result in treatment with transfusion of ≥5 units of whole blood or packed red blood cells within a 48 hour period; and chest tube output ≥2 liters (L) within a 24-hour period.
BARC type 5, fatal bleeding, describes bleeds that directly result in death with no other cause.</description>
          <population>Participants in the ITT population.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="404"/>
                <count group_id="O2" value="398"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.9"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>If non-inferiority was confirmed, then superiority analysis was pursued.</non_inferiority_desc>
            <p_value>0.2692</p_value>
            <method>Chi-squared</method>
            <param_type>Relative Risk</param_type>
            <param_value>0.77</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.48</ci_lower_limit>
            <ci_upper_limit>1.23</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Net Adverse Clinical Events (NACE) at up to 30 Days</title>
        <description>The net adverse cardiac events (NACE) at 30 days is the composite of major adverse cardiovascular events (MACE) + major bleeding (BARC type ≥3b). The composite of MACE is defined as all-cause mortality, myocardial infarction (MI), and stroke. A participant was defined to have a composite event if the participant experienced at least 1 of the components. If the participant did not have any of the components, then he or she did not have the composite endpoint. If a participant had more than 1 of the components, he or she was only counted once in the determination of the total number of participants experiencing the composite endpoint.</description>
        <time_frame>up to 30 days after procedure</time_frame>
        <population>Participants in the ITT population.</population>
        <group_list>
          <group group_id="O1">
            <title>Bivalirudin</title>
            <description>Bivalirudin administered as a bolus and intravenous (IV) infusion during TAVR. It was recommended that the bolus (0.75 milligrams per kilogram [mg/kg]) be directly administered through the valve delivery sheath immediately following its successful delivery via percutaneous femoral access. Systemic IV administration of the bolus dose was also acceptable. The bivalirudin IV infusion was initiated immediately after the bolus administration. All wires, catheters, and sheaths were to be flushed with heparinized saline.</description>
          </group>
          <group group_id="O2">
            <title>Unfractionated Heparin (UFH)</title>
            <description>The dose of UFH adhered to the standard institutional practice. An ACT target ≥250 seconds was recommended. All wires, catheters, and sheaths were to be flushed with heparinized saline.</description>
          </group>
        </group_list>
        <measure>
          <title>Net Adverse Clinical Events (NACE) at up to 30 Days</title>
          <description>The net adverse cardiac events (NACE) at 30 days is the composite of major adverse cardiovascular events (MACE) + major bleeding (BARC type ≥3b). The composite of MACE is defined as all-cause mortality, myocardial infarction (MI), and stroke. A participant was defined to have a composite event if the participant experienced at least 1 of the components. If the participant did not have any of the components, then he or she did not have the composite endpoint. If a participant had more than 1 of the components, he or she was only counted once in the determination of the total number of participants experiencing the composite endpoint.</description>
          <population>Participants in the ITT population.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="404"/>
                <count group_id="O2" value="398"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.4"/>
                    <measurement group_id="O2" value="16.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>If non-inferiority was confirmed, then superiority analysis was pursued.</non_inferiority_desc>
            <p_value>0.4967</p_value>
            <method>Chi-squared</method>
            <param_type>Relative Risk</param_type>
            <param_value>0.89</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.64</ci_lower_limit>
            <ci_upper_limit>1.24</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>NACE at 48 Hours or Before Hospital Discharge</title>
        <description>NACE at 48 hours or before hospital discharge is the composite of major adverse cardiovascular events (MACE) + major bleeding (BARC type ≥3b). The composite of MACE is defined as all-cause mortality, MI, and stroke. A participant was defined to have a composite event if the participant experienced at least 1 of the components. If the participant did not have any of the components, then he or she did not have the composite endpoint. If a participant had more than 1 of the components, he or she was only counted once in the determination of the total number of participants experiencing the composite endpoint.</description>
        <time_frame>at 48 hours or before hospital discharge, whichever occurred earlier</time_frame>
        <population>Participants in the ITT population.</population>
        <group_list>
          <group group_id="O1">
            <title>Bivalirudin</title>
            <description>Bivalirudin administered as a bolus and intravenous (IV) infusion during TAVR. It was recommended that the bolus (0.75 milligrams per kilogram [mg/kg]) be directly administered through the valve delivery sheath immediately following its successful delivery via percutaneous femoral access. Systemic IV administration of the bolus dose was also acceptable. The bivalirudin IV infusion was initiated immediately after the bolus administration. All wires, catheters, and sheaths were to be flushed with heparinized saline.</description>
          </group>
          <group group_id="O2">
            <title>Unfractionated Heparin (UFH)</title>
            <description>The dose of UFH adhered to the standard institutional practice. An ACT target ≥250 seconds was recommended. All wires, catheters, and sheaths were to be flushed with heparinized saline.</description>
          </group>
        </group_list>
        <measure>
          <title>NACE at 48 Hours or Before Hospital Discharge</title>
          <description>NACE at 48 hours or before hospital discharge is the composite of major adverse cardiovascular events (MACE) + major bleeding (BARC type ≥3b). The composite of MACE is defined as all-cause mortality, MI, and stroke. A participant was defined to have a composite event if the participant experienced at least 1 of the components. If the participant did not have any of the components, then he or she did not have the composite endpoint. If a participant had more than 1 of the components, he or she was only counted once in the determination of the total number of participants experiencing the composite endpoint.</description>
          <population>Participants in the ITT population.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="404"/>
                <count group_id="O2" value="398"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.9"/>
                    <measurement group_id="O2" value="12.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Major Adverse Cardiac Events (MACE) Including Death, Non-fatal MI, and Stroke</title>
        <description>The percentage of participants reporting a MACE overall and the individual components of MACE (including death, non-fatal MI, and stroke) are presented.</description>
        <time_frame>at 48 hours or before hospital discharge, whichever occurred earlier, and at up to 30 days (±7 days)</time_frame>
        <population>Participants in the ITT population.</population>
        <group_list>
          <group group_id="O1">
            <title>Bivalirudin</title>
            <description>Bivalirudin administered as a bolus and intravenous (IV) infusion during TAVR. It was recommended that the bolus (0.75 milligrams per kilogram [mg/kg]) be directly administered through the valve delivery sheath immediately following its successful delivery via percutaneous femoral access. Systemic IV administration of the bolus dose was also acceptable. The bivalirudin IV infusion was initiated immediately after the bolus administration. All wires, catheters, and sheaths were to be flushed with heparinized saline.</description>
          </group>
          <group group_id="O2">
            <title>Unfractionated Heparin (UFH)</title>
            <description>The dose of UFH adhered to the standard institutional practice. An ACT target ≥250 seconds was recommended. All wires, catheters, and sheaths were to be flushed with heparinized saline.</description>
          </group>
        </group_list>
        <measure>
          <title>Major Adverse Cardiac Events (MACE) Including Death, Non-fatal MI, and Stroke</title>
          <description>The percentage of participants reporting a MACE overall and the individual components of MACE (including death, non-fatal MI, and stroke) are presented.</description>
          <population>Participants in the ITT population.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="404"/>
                <count group_id="O2" value="398"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>MACE at 48 hours or before hospital discharge</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.5"/>
                    <measurement group_id="O2" value="4.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Death at 48 hours or before hospital discharge</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5"/>
                    <measurement group_id="O2" value="1.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MI at 48 hours or before hospital discharge</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stroke at 48 hours or before hospital discharge</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MACE at up to 30 days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.7"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Death at up to 30 days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.7"/>
                    <measurement group_id="O2" value="4.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MI at up to 30 days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5"/>
                    <measurement group_id="O2" value="1.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stroke at up to 30 days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.5"/>
                    <measurement group_id="O2" value="2.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Major Bleeding According to Additional Scales (VARC, TIMI, GUSTO, ACUITY/HORIZONS)</title>
        <description>Percentage of participants with major bleeding according to the following scales:
Valve Academic Research Consortium (VARC)=life threatening, disabling bleeding, or major bleeding
Thrombolysis in Myocardial Infarction (TIMI)=major bleeding
Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO)=severe or moderate
Acute Catheterization and Urgent Intervention Triage StrategY (ACUITY)/Harmonizing Outcomes with RevasculariZatiON and Stents (HORIZONS)=major bleeding</description>
        <time_frame>at 48 hours or hospital discharge, whichever occurred earlier, and at up to 30 days (±7 days) follow-up</time_frame>
        <population>Participants in the ITT population.</population>
        <group_list>
          <group group_id="O1">
            <title>Bivalirudin</title>
            <description>Bivalirudin administered as a bolus and intravenous (IV) infusion during TAVR. It was recommended that the bolus (0.75 milligrams per kilogram [mg/kg]) be directly administered through the valve delivery sheath immediately following its successful delivery via percutaneous femoral access. Systemic IV administration of the bolus dose was also acceptable. The bivalirudin IV infusion was initiated immediately after the bolus administration. All wires, catheters, and sheaths were to be flushed with heparinized saline.</description>
          </group>
          <group group_id="O2">
            <title>Unfractionated Heparin (UFH)</title>
            <description>The dose of UFH adhered to the standard institutional practice. An ACT target ≥250 seconds was recommended. All wires, catheters, and sheaths were to be flushed with heparinized saline.</description>
          </group>
        </group_list>
        <measure>
          <title>Major Bleeding According to Additional Scales (VARC, TIMI, GUSTO, ACUITY/HORIZONS)</title>
          <description>Percentage of participants with major bleeding according to the following scales:
Valve Academic Research Consortium (VARC)=life threatening, disabling bleeding, or major bleeding
Thrombolysis in Myocardial Infarction (TIMI)=major bleeding
Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO)=severe or moderate
Acute Catheterization and Urgent Intervention Triage StrategY (ACUITY)/Harmonizing Outcomes with RevasculariZatiON and Stents (HORIZONS)=major bleeding</description>
          <population>Participants in the ITT population.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="404"/>
                <count group_id="O2" value="398"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>VARC at 48 hours or before hospital</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.8"/>
                    <measurement group_id="O2" value="19.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TIMI at 48 hours or before hospital</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="6.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GUSTO at 48 hours or hospital discharge</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.9"/>
                    <measurement group_id="O2" value="11.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACUITY/HORIZONS at 48 hours or hospital discharge</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26"/>
                    <measurement group_id="O2" value="24.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>VARC at 30 days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.5"/>
                    <measurement group_id="O2" value="24.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TIMI at 30 days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.7"/>
                    <measurement group_id="O2" value="7.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GUSTO at 30 days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.3"/>
                    <measurement group_id="O2" value="14.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACUITY/HORIZONS at 30 days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.4"/>
                    <measurement group_id="O2" value="29.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Transient Ischemic Attack</title>
        <description>The percentage of participants reporting transient ischemic attack is presented.</description>
        <time_frame>at 48 hours or before hospital discharge, whichever occurred earlier, and at up to 30 days (±7 days)</time_frame>
        <population>Participants in the ITT population.</population>
        <group_list>
          <group group_id="O1">
            <title>Bivalirudin</title>
            <description>Bivalirudin administered as a bolus and intravenous (IV) infusion during TAVR. It was recommended that the bolus (0.75 milligrams per kilogram [mg/kg]) be directly administered through the valve delivery sheath immediately following its successful delivery via percutaneous femoral access. Systemic IV administration of the bolus dose was also acceptable. The bivalirudin IV infusion was initiated immediately after the bolus administration. All wires, catheters, and sheaths were to be flushed with heparinized saline.</description>
          </group>
          <group group_id="O2">
            <title>Unfractionated Heparin (UFH)</title>
            <description>The dose of UFH adhered to the standard institutional practice. An ACT target ≥250 seconds was recommended. All wires, catheters, and sheaths were to be flushed with heparinized saline.</description>
          </group>
        </group_list>
        <measure>
          <title>Transient Ischemic Attack</title>
          <description>The percentage of participants reporting transient ischemic attack is presented.</description>
          <population>Participants in the ITT population.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="404"/>
                <count group_id="O2" value="398"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>at 48 hours or before hospital discharge</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>at up to 30 days (±7 days) follow-up</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Acute Kidney Injury</title>
        <description>The percentage of participants reporting acute kidney injury is presented.</description>
        <time_frame>at 48 hours or hospital discharge, whichever occurred earlier, and at up to 30 days (±7 days) follow-up</time_frame>
        <population>Participants in the ITT population.</population>
        <group_list>
          <group group_id="O1">
            <title>Bivalirudin</title>
            <description>Bivalirudin administered as a bolus and intravenous (IV) infusion during TAVR. It was recommended that the bolus (0.75 milligrams per kilogram [mg/kg]) be directly administered through the valve delivery sheath immediately following its successful delivery via percutaneous femoral access. Systemic IV administration of the bolus dose was also acceptable. The bivalirudin IV infusion was initiated immediately after the bolus administration. All wires, catheters, and sheaths were to be flushed with heparinized saline.</description>
          </group>
          <group group_id="O2">
            <title>Unfractionated Heparin (UFH)</title>
            <description>The dose of UFH adhered to the standard institutional practice. An ACT target ≥250 seconds was recommended. All wires, catheters, and sheaths were to be flushed with heparinized saline.</description>
          </group>
        </group_list>
        <measure>
          <title>Acute Kidney Injury</title>
          <description>The percentage of participants reporting acute kidney injury is presented.</description>
          <population>Participants in the ITT population.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="404"/>
                <count group_id="O2" value="398"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>at 48 hours or before hospital discharge</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.9"/>
                    <measurement group_id="O2" value="6.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>at up to 30 days (±7 days) follow-up</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.8"/>
                    <measurement group_id="O2" value="13.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Major Vascular Complications</title>
        <description>The percentage of participants reporting a major vascular complications as defined by VARC is presented.</description>
        <time_frame>at 48 hours or before hospital discharge, whichever occurred earlier, and at up to 30 days (±7 days)</time_frame>
        <population>Participants in the ITT population.</population>
        <group_list>
          <group group_id="O1">
            <title>Bivalirudin</title>
            <description>Bivalirudin administered as a bolus and intravenous (IV) infusion during TAVR. It was recommended that the bolus (0.75 milligrams per kilogram [mg/kg]) be directly administered through the valve delivery sheath immediately following its successful delivery via percutaneous femoral access. Systemic IV administration of the bolus dose was also acceptable. The bivalirudin IV infusion was initiated immediately after the bolus administration. All wires, catheters, and sheaths were to be flushed with heparinized saline.</description>
          </group>
          <group group_id="O2">
            <title>Unfractionated Heparin (UFH)</title>
            <description>The dose of UFH adhered to the standard institutional practice. An ACT target ≥250 seconds was recommended. All wires, catheters, and sheaths were to be flushed with heparinized saline.</description>
          </group>
        </group_list>
        <measure>
          <title>Major Vascular Complications</title>
          <description>The percentage of participants reporting a major vascular complications as defined by VARC is presented.</description>
          <population>Participants in the ITT population.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="404"/>
                <count group_id="O2" value="398"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>at 48 hours or before hospital discharge</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.7"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>at up to 30 days (±7 days) follow-up</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.2"/>
                    <measurement group_id="O2" value="9.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Acquired Thrombocytopenia</title>
        <description>The percentage of participants reporting acquired thrombocytopenia is presented.</description>
        <time_frame>at 48 hours or before hospital discharge, whichever occurred earlier, and at up to 30 days (±7 days)</time_frame>
        <population>Participants in the ITT population.</population>
        <group_list>
          <group group_id="O1">
            <title>Bivalirudin</title>
            <description>Bivalirudin administered as a bolus and intravenous (IV) infusion during TAVR. It was recommended that the bolus (0.75 milligrams per kilogram [mg/kg]) be directly administered through the valve delivery sheath immediately following its successful delivery via percutaneous femoral access. Systemic IV administration of the bolus dose was also acceptable. The bivalirudin IV infusion was initiated immediately after the bolus administration. All wires, catheters, and sheaths were to be flushed with heparinized saline.</description>
          </group>
          <group group_id="O2">
            <title>Unfractionated Heparin (UFH)</title>
            <description>The dose of UFH adhered to the standard institutional practice. An ACT target ≥250 seconds was recommended. All wires, catheters, and sheaths were to be flushed with heparinized saline.</description>
          </group>
        </group_list>
        <measure>
          <title>Acquired Thrombocytopenia</title>
          <description>The percentage of participants reporting acquired thrombocytopenia is presented.</description>
          <population>Participants in the ITT population.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="404"/>
                <count group_id="O2" value="398"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>at 48 hours or before hospital discharge</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.6"/>
                    <measurement group_id="O2" value="17.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>at up to 30 days (±7 days)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                    <measurement group_id="O2" value="23.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>New Onset Atrial Fibrillation/Flutter</title>
        <description>The percentage of participants reporting new onset atrial fibrillation/flutter is presented.</description>
        <time_frame>at 48 hours or before hospital discharge, whichever occurred earlier, and at up to 30 days (±7 days)</time_frame>
        <population>Participants in the ITT population.</population>
        <group_list>
          <group group_id="O1">
            <title>Bivalirudin</title>
            <description>Bivalirudin administered as a bolus and intravenous (IV) infusion during TAVR. It was recommended that the bolus (0.75 milligrams per kilogram [mg/kg]) be directly administered through the valve delivery sheath immediately following its successful delivery via percutaneous femoral access. Systemic IV administration of the bolus dose was also acceptable. The bivalirudin IV infusion was initiated immediately after the bolus administration. All wires, catheters, and sheaths were to be flushed with heparinized saline.</description>
          </group>
          <group group_id="O2">
            <title>Unfractionated Heparin (UFH)</title>
            <description>The dose of UFH adhered to the standard institutional practice. An ACT target ≥250 seconds was recommended. All wires, catheters, and sheaths were to be flushed with heparinized saline.</description>
          </group>
        </group_list>
        <measure>
          <title>New Onset Atrial Fibrillation/Flutter</title>
          <description>The percentage of participants reporting new onset atrial fibrillation/flutter is presented.</description>
          <population>Participants in the ITT population.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="404"/>
                <count group_id="O2" value="398"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>at 48 hours or before hospital discharge</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.2"/>
                    <measurement group_id="O2" value="2.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>at up to 30 days (±7 days) follow-up</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.4"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Timing Effect on Bleeding Event Rate up to 48 Hours or Hospital Discharge</title>
        <description>The effect of timing on bleeding event rates (the percentage of participants with an incidence of major bleeding) is presented.</description>
        <time_frame>Up to 48 hours after procedure or at hospital discharge (but also includes any subsequent hospitalizations)</time_frame>
        <population>Participants in the ITT population with an incidence of major bleeding. Participants were categorized as &quot;First half of study site's enrolled participants&quot; (Bivalirudin, N=173; UFH, N=173) and &quot;Second half of study site's enrolled participants&quot; (Bivalirudin, N=171; UFH, N=165). Only sites with &gt;20 participants are included in this analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Bivalirudin: First Half of Study Site's Enrolled Participants</title>
            <description>Bivalirudin administered as a bolus and intravenous (IV) infusion during TAVR. It was recommended that the bolus (0.75 milligrams per kilogram [mg/kg]) be directly administered through the valve delivery sheath immediately following its successful delivery via percutaneous femoral access. Systemic IV administration of the bolus dose was also acceptable. The bivalirudin IV infusion was initiated immediately after the bolus administration. All wires, catheters, and sheaths were to be flushed with heparinized saline. This includes the first half of the site’s enrolled participants, and only sites with more than 20 participants are included in this analysis.</description>
          </group>
          <group group_id="O2">
            <title>Bivalirudin: Second Half of Study Site's Enrolled Participants</title>
            <description>Bivalirudin administered as a bolus and intravenous (IV) infusion during TAVR. It was recommended that the bolus (0.75 milligrams per kilogram [mg/kg]) be directly administered through the valve delivery sheath immediately following its successful delivery via percutaneous femoral access. Systemic IV administration of the bolus dose was also acceptable. The bivalirudin IV infusion was initiated immediately after the bolus administration. All wires, catheters, and sheaths were to be flushed with heparinized saline. This includes the second half of the site’s enrolled participants, and only sites with more than 20 participants are included in this analysis.</description>
          </group>
          <group group_id="O3">
            <title>UFH: First Half of Study Site's Enrolled Participants</title>
            <description>The dose of UFH adhered to the standard institutional practice. An ACT target ≥250 seconds was recommended. All wires, catheters, and sheaths were to be flushed with heparinized saline. This includes the first half of the site’s enrolled participants, and only sites with more than 20 participants are included in this analysis.</description>
          </group>
          <group group_id="O4">
            <title>UFH: Second Half of Study Site's Enrolled Participants</title>
            <description>The dose of UFH adhered to the standard institutional practice. An ACT target ≥250 seconds was recommended. All wires, catheters, and sheaths were to be flushed with heparinized saline. This includes the second half of the site’s enrolled participants, and only sites with more than 20 participants are included in this analysis.</description>
          </group>
        </group_list>
        <measure>
          <title>Timing Effect on Bleeding Event Rate up to 48 Hours or Hospital Discharge</title>
          <description>The effect of timing on bleeding event rates (the percentage of participants with an incidence of major bleeding) is presented.</description>
          <population>Participants in the ITT population with an incidence of major bleeding. Participants were categorized as &quot;First half of study site's enrolled participants&quot; (Bivalirudin, N=173; UFH, N=173) and &quot;Second half of study site's enrolled participants&quot; (Bivalirudin, N=171; UFH, N=165). Only sites with &gt;20 participants are included in this analysis.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="173"/>
                <count group_id="O2" value="171"/>
                <count group_id="O3" value="173"/>
                <count group_id="O4" value="165"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.4"/>
                    <measurement group_id="O2" value="6.4"/>
                    <measurement group_id="O3" value="11.6"/>
                    <measurement group_id="O4" value="8.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Bleeding BARC 3a, BARC Types 1 or 2, and TIMI Minor</title>
        <description>The percentage of participants with moderate bleeding as defined by BARC 3a and minor bleeding as defined as BARC type 1 and 2 and TIMI minor is presented.</description>
        <time_frame>at 48 hours or hospital discharge, whichever occurred earlier, and at up to 30 days (±7 days) follow-up</time_frame>
        <population>Participants in the ITT population.</population>
        <group_list>
          <group group_id="O1">
            <title>Bivalirudin</title>
            <description>Bivalirudin administered as a bolus and intravenous (IV) infusion during TAVR. It was recommended that the bolus (0.75 milligrams per kilogram [mg/kg]) be directly administered through the valve delivery sheath immediately following its successful delivery via percutaneous femoral access. Systemic IV administration of the bolus dose was also acceptable. The bivalirudin IV infusion was initiated immediately after the bolus administration. All wires, catheters, and sheaths were to be flushed with heparinized saline.</description>
          </group>
          <group group_id="O2">
            <title>Unfractionated Heparin (UFH)</title>
            <description>The dose of UFH adhered to the standard institutional practice. An ACT target ≥250 seconds was recommended. All wires, catheters, and sheaths were to be flushed with heparinized saline.</description>
          </group>
        </group_list>
        <measure>
          <title>Bleeding BARC 3a, BARC Types 1 or 2, and TIMI Minor</title>
          <description>The percentage of participants with moderate bleeding as defined by BARC 3a and minor bleeding as defined as BARC type 1 and 2 and TIMI minor is presented.</description>
          <population>Participants in the ITT population.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="404"/>
                <count group_id="O2" value="398"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>BARC 3a at 48 hours or hospital discharge</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.6"/>
                    <measurement group_id="O2" value="13.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BARC types 1 and 2 at 48 hours or discharge</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.8"/>
                    <measurement group_id="O2" value="21.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TIMI minor at 48 hours or hospital discharge</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.6"/>
                    <measurement group_id="O2" value="14.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BARC 3a at 30 days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.8"/>
                    <measurement group_id="O2" value="17.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BARC types 1 and 2 at 30 days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.7"/>
                    <measurement group_id="O2" value="25.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TIMI minor at 30 days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.3"/>
                    <measurement group_id="O2" value="19.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Bivalirudin</title>
          <description>Bivalirudin administered as a bolus and intravenous (IV) infusion during TAVR. It was recommended that the bolus (0.75 milligrams per kilogram [mg/kg]) be directly administered through the valve delivery sheath immediately following its successful delivery via percutaneous femoral access. Systemic IV administration of the bolus dose was also acceptable. The bivalirudin IV infusion was initiated immediately after the bolus administration. All wires, catheters, and sheaths were to be flushed with heparinized saline.</description>
        </group>
        <group group_id="E2">
          <title>Unfractionated Heparin (UFH)</title>
          <description>The dose of UFH adhered to the standard institutional practice. An ACT target ≥250 seconds was recommended. All wires, catheters, and sheaths were to be flushed with heparinized saline.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 15.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="112" subjects_at_risk="393"/>
                <counts group_id="E2" subjects_affected="116" subjects_at_risk="394"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrioventricular block complete</sub_title>
                <counts group_id="E1" subjects_affected="46" subjects_at_risk="393"/>
                <counts group_id="E2" subjects_affected="34" subjects_at_risk="394"/>
              </event>
              <event>
                <sub_title>Bundle branch block left</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="393"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="394"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="393"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="394"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="393"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="394"/>
              </event>
              <event>
                <sub_title>Atrioventricular block second degree</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="393"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="394"/>
              </event>
              <event>
                <sub_title>Atrioventricular block first degree</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="393"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="394"/>
              </event>
              <event>
                <sub_title>Atrioventricular block</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="393"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="394"/>
              </event>
              <event>
                <sub_title>Ventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="393"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="394"/>
              </event>
              <event>
                <sub_title>Cardiac failure acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="393"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="394"/>
              </event>
              <event>
                <sub_title>Aortic valve incompetence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="393"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="394"/>
              </event>
              <event>
                <sub_title>Cardiac tamponade</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="393"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="394"/>
              </event>
              <event>
                <sub_title>Cardiogenic shock</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="393"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="394"/>
              </event>
              <event>
                <sub_title>Coronary artery occlusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="393"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="394"/>
              </event>
              <event>
                <sub_title>Ventricular fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="393"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="394"/>
              </event>
              <event>
                <sub_title>Ventricular tachyarrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="393"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="394"/>
              </event>
              <event>
                <sub_title>Bifascicular block</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="393"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="394"/>
              </event>
              <event>
                <sub_title>Bradyarrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="393"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="394"/>
              </event>
              <event>
                <sub_title>Cardiac perforation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="393"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="394"/>
              </event>
              <event>
                <sub_title>Cardio-respiratory arrest</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="393"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="394"/>
              </event>
              <event>
                <sub_title>Cardiopulmonary failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="393"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="394"/>
              </event>
              <event>
                <sub_title>Coronary artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="393"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="394"/>
              </event>
              <event>
                <sub_title>Ischaemic cardiomyopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="393"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="394"/>
              </event>
              <event>
                <sub_title>Low cardiac output syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="393"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="394"/>
              </event>
              <event>
                <sub_title>Pericardial effusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="393"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="394"/>
              </event>
              <event>
                <sub_title>Sick sinus syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="393"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="394"/>
              </event>
              <event>
                <sub_title>Supraventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="393"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="394"/>
              </event>
              <event>
                <sub_title>Bundle branch block</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="393"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="394"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="393"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="394"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Retroperitoneal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="393"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="394"/>
              </event>
              <event>
                <sub_title>Abdominal hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="393"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="394"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="393"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="394"/>
              </event>
              <event>
                <sub_title>Gastric haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="393"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="394"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="393"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="394"/>
              </event>
              <event>
                <sub_title>Intestinal infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="393"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="394"/>
              </event>
              <event>
                <sub_title>Intestinal ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="393"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="394"/>
              </event>
              <event>
                <sub_title>Umbilical hernia, obstructive</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="393"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="394"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <description>Organ system includes administration site conditions.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="393"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="394"/>
              </event>
              <event>
                <sub_title>Device leakage</sub_title>
                <description>Organ system includes administration site conditions.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="393"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="394"/>
              </event>
              <event>
                <sub_title>Thrombosis in device</sub_title>
                <description>Organ system includes administration site conditions.</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="393"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="394"/>
              </event>
              <event>
                <sub_title>Device dislocation</sub_title>
                <description>Organ system includes administration site conditions.</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="393"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="394"/>
              </event>
              <event>
                <sub_title>General physical health deterioration</sub_title>
                <description>Organ system includes administration site conditions.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="393"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="394"/>
              </event>
              <event>
                <sub_title>Hyperthermia</sub_title>
                <description>Organ system includes administration site conditions.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="393"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="394"/>
              </event>
              <event>
                <sub_title>Multi-organ failure</sub_title>
                <description>Organ system includes administration site conditions.</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="393"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="394"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <description>Organ system includes administration site conditions.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="393"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="394"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <description>Organ system includes administration site conditions.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="393"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="394"/>
              </event>
              <event>
                <sub_title>Sudden death</sub_title>
                <description>Organ system includes administration site conditions.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="393"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="394"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="393"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="394"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaphylactic shock</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="393"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="394"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="393"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="394"/>
              </event>
              <event>
                <sub_title>Bronchopneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="393"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="394"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="393"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="394"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="393"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="394"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="393"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="394"/>
              </event>
              <event>
                <sub_title>Intervertebral discitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="393"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="394"/>
              </event>
              <event>
                <sub_title>Klebsiella infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="393"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="394"/>
              </event>
              <event>
                <sub_title>Pneumonia viral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="393"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="394"/>
              </event>
              <event>
                <sub_title>Postoperative wound infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="393"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="394"/>
              </event>
              <event>
                <sub_title>Pseudomonas infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="393"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="394"/>
              </event>
              <event>
                <sub_title>Septic encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="393"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="394"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="393"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="394"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Cardiac valve replacement</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="393"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="394"/>
              </event>
              <event>
                <sub_title>Cardiac valve rupture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="393"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="394"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="393"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="394"/>
              </event>
              <event>
                <sub_title>Pneumothorax traumatic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="393"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="394"/>
              </event>
              <event>
                <sub_title>Vascular procedure complication</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="393"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="394"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetes mellitus inadequate control</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="393"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="394"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="393"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="394"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Colon cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="393"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="394"/>
              </event>
              <event>
                <sub_title>Bladder cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="393"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="394"/>
              </event>
              <event>
                <sub_title>Gastric cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="393"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="394"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Ischaemic stroke</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="393"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="394"/>
              </event>
              <event>
                <sub_title>Carotid artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="393"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="394"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="393"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="394"/>
              </event>
              <event>
                <sub_title>Cognitive disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="393"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="394"/>
              </event>
              <event>
                <sub_title>Haemorrhage intracranial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="393"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="394"/>
              </event>
              <event>
                <sub_title>Haemorrhagic stroke</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="393"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="394"/>
              </event>
              <event>
                <sub_title>Loss of consciousness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="393"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="394"/>
              </event>
              <event>
                <sub_title>Myasthenia gravis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="393"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="394"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="393"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="394"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Confusional state</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="393"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="394"/>
              </event>
              <event>
                <sub_title>Panic attack</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="393"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="394"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="393"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="394"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="393"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="394"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="393"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="394"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="393"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="394"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="393"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="394"/>
              </event>
              <event>
                <sub_title>Pleurisy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="393"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="394"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="393"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="394"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="393"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="394"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Intestinal anastomosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="393"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="394"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="393"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="394"/>
              </event>
              <event>
                <sub_title>Peripheral ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="393"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="394"/>
              </event>
              <event>
                <sub_title>Aortic dissection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="393"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="394"/>
              </event>
              <event>
                <sub_title>Circulatory collapse</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="393"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="394"/>
              </event>
              <event>
                <sub_title>Femoral artery dissection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="393"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="394"/>
              </event>
              <event>
                <sub_title>Haemodynamic instability</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="393"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="394"/>
              </event>
              <event>
                <sub_title>Hypertensive crisis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="393"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="394"/>
              </event>
              <event>
                <sub_title>Peripheral arterial occlusive disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="393"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="394"/>
              </event>
              <event>
                <sub_title>Peripheral artery thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="393"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="394"/>
              </event>
              <event>
                <sub_title>Phlebitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="393"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="394"/>
              </event>
              <event>
                <sub_title>Shock</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="393"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="394"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>3</frequency_threshold>
        <default_vocab>MedDRA 15.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="73" subjects_at_risk="393"/>
                <counts group_id="E2" subjects_affected="70" subjects_at_risk="394"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Bundle branch block left</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="393"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="394"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <description>Organ system includes administration site conditions.</description>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="393"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="394"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="393"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="394"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Confusional state</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="393"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="394"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="393"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="394"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Global Health Science Center</name_or_title>
      <organization>The Medicines Company</organization>
      <phone>800-388-1183</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

